Cellectis (NASDAQ:CLLS) Earns Buy Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Cellectis (NASDAQ:CLLS) in a research report sent to investors on Friday. The brokerage issued a buy rating on the biotechnology company’s stock.

Separately, Barclays cut their price objective on shares of Cellectis from $7.00 to $5.00 and set an “overweight” rating for the company in a report on Tuesday, November 5th.

Cellectis Price Performance

Shares of CLLS opened at $1.67 on Friday. The company has a market capitalization of $92.82 million, a P/E ratio of -1.28 and a beta of 3.08. The business’s 50-day moving average is $1.80 and its two-hundred day moving average is $1.98. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.78 and a current ratio of 1.78. Cellectis has a fifty-two week low of $1.41 and a fifty-two week high of $3.38.

Cellectis (NASDAQ:CLLS) last announced its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.03). The company had revenue of $18.05 million for the quarter, compared to analysts’ expectations of $5.00 million. Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. During the same quarter in the prior year, the business posted ($0.31) earnings per share. Research analysts predict that Cellectis will post -0.46 earnings per share for the current year.

Institutional Investors Weigh In On Cellectis

Institutional investors have recently added to or reduced their stakes in the stock. Long Focus Capital Management LLC raised its position in Cellectis by 2.9% during the second quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock worth $8,634,000 after acquiring an additional 130,000 shares during the period. First Affirmative Financial Network purchased a new stake in shares of Cellectis during the third quarter worth about $45,000. Finally, XTX Topco Ltd acquired a new position in shares of Cellectis during the 2nd quarter worth about $29,000. Institutional investors and hedge funds own 63.90% of the company’s stock.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.